Dordaviprone: all 25 studies that test it
Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Testing for Safety and Colorectal Cancer Preventive Effects of ONC201RecruitingNCT05630794Phase 1
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)RecruitingNCT05580562Phase 3
- ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingNCT05542407Phase 1
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingNCT05476939Phase 3
- Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingNCT05009992Phase 2
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingNCT04055649Phase 2
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerTerminatedNCT03485729Phase 2Results posted
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
- ONC201 in Adults With Recurrent H3 K27M-mutant GliomaTerminatedNCT03295396Phase 2Results posted
- Single Agent ONC201 in Recurrent or Metastatic Endometrial CancerTerminatedNCT03099499Phase 2Results posted
- Phase 2 Study of ONC201 in Neuroendocrine TumorsCompletedNCT03034200Phase 2Results posted
- Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedNCT02863991Phase 1/2Results posted
- Oral ONC201 in Adult Recurrent GlioblastomaTerminatedNCT02525692Phase 2Results posted
- Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT02420795Phase 1/2Results posted
- A Study of ONC201 for Refractory MeningiomaWithdrawnNCT06012929Phase 2
- ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent GlioblastomaWithdrawnNCT04854044Phase 1
- A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaWithdrawnNCT04629209Phase 2
- ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantCompletedNCT03932643Phase 1
- Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT03492138Phase 1/2
- ONC201 in Pediatric H3 K27M GliomasTerminatedNCT03416530Phase 1
- A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple MyelomaCompletedNCT02609230Phase 1
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT02392572Phase 1/2
- Continuation of Oral ONC201 in Treating Patients With Advanced Solid TumorsCompletedNCT02324621Phase 1
- Oral ONC201 in Treating Patients With Advanced Solid TumorsCompletedNCT02250781Phase 1
- A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced CancerWithdrawnNCT02038699Phase 1/2